Issue 15, 2025

Continuous synthesis of PEGylated MIL-101(Cr) nanoparticles for neuroprotection

Abstract

The application of metal organic frameworks (MOFs) in targeted drug delivery for ischemic stroke therapy has emerged as a hot issue recently. Although significant progress has been made in immobilizing neuroprotective agents on MOFs, environmentally friendly large-scale preparation of nano-drug-loaded MOFs with controlled size, morphology, purity and therapeutic effect remains challenging. PEGylation of MIL-101(Cr) nanoparticles with dual ligands that have the 2,2-dimethylthiazolidine (DMTD) structure was developed in this work to mitigate nervous system injury induced by ischemia/reperfusion (IR) during a stroke. A green ultrasound-assisted continuous-flow system was established for efficient production of the versatile MOF nanoparticles. Unified nanoparticles (diameter: ∼250–350 nm) were obtained with both high quality and high space-time yield (5664 kg m−3 d−1). The MOF exhibited protective activity in SH-SY5Y cells against oxygen and glucose deprivation and H2O2 insults, and prevented reactive oxygen species accumulation. The cellular uptake of the PEGylated MOFs by brain capillary endothelial cells was investigated, showing targeting capability in vitro, which proposes the biomaterial as a promising therapeutic candidate for reducing IR-induced nervous system injury.

Graphical abstract: Continuous synthesis of PEGylated MIL-101(Cr) nanoparticles for neuroprotection

Supplementary files

Article information

Article type
Paper
Submitted
31 ဒီ 2024
Accepted
05 ဧပြီ 2025
First published
16 ဧပြီ 2025
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2025,15, 12020-12027

Continuous synthesis of PEGylated MIL-101(Cr) nanoparticles for neuroprotection

Y. Wang and S. Li, RSC Adv., 2025, 15, 12020 DOI: 10.1039/D4RA09107H

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements